Evidence map›Paper›PMID 39950746›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Hybrid Outer Membrane Vesicles with Genetically Engineering for Treatment of Implant-Associated Infections and Relapse Prevention Through Host Immunomodulation.

Zhichao Wang, Mingfei Li, Wenshuai Li, Liuliang He, Long Wang, Kehan Cai, Xiao Zhao, Yazhou Chen, Daifeng Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Clinical features ofFrontiers in cellular and infection microbiology · 2026
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhichao WangDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Mingfei LiDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Wenshuai LiMedical 3D Printing Center, The First Affiliated Hospital of Zhengzhou University, Henan Institute of Advanced Technology of Zhengzhou University, Zhengzhou, 450052, China.
Liuliang HeDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Long WangDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Kehan CaiDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Xiao ZhaoCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing, 100190, China.
Yazhou ChenMedical 3D Printing Center, The First Affiliated Hospital of Zhengzhou University, Henan Institute of Advanced Technology of Zhengzhou University, Zhengzhou, 450052, China.
Daifeng LiDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.ORCID https://orcid.org/0000-0002-6727-2153

Funding

Clinical Medical Scientist of Henan Academy of Innovations in Medical Science S20240059National Natural Science Foundation of China 82102588Natural Science Foundation of Henan Province 232300421050Natural Science Foundation of Henan Province 242301420068Young and Middle-Aged Discipline Leader of Henan Provincial Health Commission HNSWJW2022007Young Elite Scientists Sponsorship Program by CAST 2023QNRC001
6 · The paper itself

Abstract

Implant-associated infections (IAIs) are refractory to elimination, and the local immunosuppressive microenvironment (IME) exacerbates therapeutic difficulties, ultimately causing persistence and relapse. Therefore, exploring immunostrengthening treatments holds great promise for reversing IME and thoroughly eradicating chronic or repetitive infections. Bacterial outer membrane vesicles (OMVs) have emerged as potential immunostimulatory candidates; however, they lack active targeting capabilities and cause non-specific inflammatory side effects. In this study, bone marrow-derived mesenchymal stem cells (BMSCs) are genetically engineered to overexpress CXCR4 and isolated cell membranes (mBMSC

Indexed as

Bacterial Outer MembraneGenetic EngineeringImmunomodulationProsthesis-Related InfectionsAnimalsEscherichia coliExtracellular VesiclesMesenchymal Stem CellsMiceMice, Inbred C57BLSecondary Preventionbacterial outer membrane vesiclesbone marrow targetingimmunomodulationimplant‐associated infectionsrelapse prevention

Identifiers

PMID39950746
PMCPMC11984893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.